Trials / Completed
CompletedNCT07424911
α-N-acetylgalactosaminidase Levels in Panic Disorder
α-N-acetylgalactosaminidase Levels in Panic Disorder: A Prospective Observational Cohort Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 66 (actual)
- Sponsor
- Elazığ Mental Health and Diseases Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This prospective observational cohort study investigated serum α-N-acetylgalactosaminidase levels in drug-naïve patients with Panic Disorder (PD) at baseline and after six weeks of follow-up and compared them with healthy controls (HC). Associations between enzyme levels, symptom severity, and inflammatory markers were examined. The study aimed to evaluate whether α-N-acetylgalactosaminidase levels are associated with PD symptom severity and inflammatory parameters.
Detailed description
Panic Disorder (PD) is associated with increased inflammatory markers. α-N-acetylgalactosaminidase mediates deglycosylation of vitamin D-binding protein (Gc protein), affecting macrophage activation and immune regulation. Its role in anxiety disorders has not been previously examined. Thirty-three drug-naïve patients with PD and 33 healthy controls (HC) were enrolled. Patients with PD were evaluated at baseline and after six weeks of standard clinical treatment. Serum α-N-acetylgalactosaminidase levels were measured using ELISA. DSM-5 Panic Disorder Scale (PDS) scores and complete blood count inflammatory parameters were recorded. No intervention was assigned as part of the research protocol. Participants received routine clinical care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention was assigned as part of the research protocol. Participants with PD received routine clinical care. | No intervention was assigned as part of the research protocol. Participants with PD received routine clinical care. |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2025-06-16
- Completion
- 2025-08-01
- First posted
- 2026-02-20
- Last updated
- 2026-02-20
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT07424911. Inclusion in this directory is not an endorsement.